Vyome Holdings, Inc.

Stage 4 · Declining · week 8

As of Oct 22, 2026, Vyome Holdings is in Stage 4, the downtrend phase, now in week 8 (since Aug 31, 2026). It closed at $1.80, 71.5% below its 52-week high and below its 200-day average, which is falling.

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. More about the company

$1.80

-2.17% today

$12.6M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is HIND early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 21w

S4 17w

S4 96w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 21w → S1 1w → S4 17w → S1 10w → S2 1w → S1 1w → S4 96w → S1 10w → S4 8w current

Total tracked: 165 weeks across 9 stage runs.

HIND among Biotechnology418th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…418	HINDVyome Holdings, Inc.	Stage 4 · wk 8	16	−10.4%

vs 52W High

-71.5%

$1.80 lo$6.31 hi

71.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 8

1w13w26w

Week 8, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-21.4%

200 DMA: $2.29 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.78x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-10.4%

-12.6%

-20.4%

YTD

-49.3%

-66.9%

Scan Membership

Breakout Watch

Latest: 2024-07-31

2 appearances in last 60 days. First seen: 2020-12-01.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 8 · Vol 0.78x

2026-10-21S4

Wk 8 · Vol 0.15x

2026-10-20S4

Wk 8 · Vol 0.60x

2026-10-19S4

Wk 7 · Vol 0.65x

2026-10-16S4

Wk 7 · Vol 0.82x

2026-10-15S4

Wk 7 · Vol 1.11x

2026-10-14S4

Wk 7 · Vol 0.47x

2026-10-13S4

Wk 7 · Vol 0.74x

2026-10-12S4

Wk 6 · Vol 0.51x

2026-10-09S4

Wk 6 · Vol 0.55x

2026-10-08S4

Wk 6 · Vol 0.59x

2026-10-07S4

Wk 6 · Vol 0.84x

Moving averages & range

50 DMA

$2.06

200 DMA

$2.29

52W High

$6.31

52W Low

$1.80

5D Low

$1.80

Resistance levels (recent highs)

20d High

$2.09

60d High

$2.32

120d High

$2.35

250d High

$6.31

Next resistance

+16.1%

to 20d High

P/E (TTM)

1.0

Forward —

ROE

-999.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.1

Vyome Holdings: quick answers

What stage is Vyome Holdings in?

As of Oct 22, 2026, Vyome Holdings (HIND) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 31, 2026 and is in week 8. What the four stages mean

Is Vyome Holdings in an uptrend?

No. Vyome Holdings is in a Stage 4 downtrend. It trades 21.4% below its 200-day average, which is falling.

How far is Vyome Holdings from its 52-week high?

Vyome Holdings closed at $1.80 on Oct 22, 2026, 71.5% below its 52-week high of $6.31. Its 52-week low is $1.80.

How has Vyome Holdings performed over the past year?

As of Oct 22, 2026, Vyome Holdings is down 66.9% over the past year and down 49.3% so far in 2026.

Which sector and industry is Vyome Holdings in?

Vyome Holdings is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.